Human VEGFR2 Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-Human VEGFR2 antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Human VEGFR2 |
| Clone | [BEP-5A1] |
| Host Species | Rat |
| Reactive Species | n/a |
| Isotype | IgG2a/kappa |
| Format | Protein G purified |
| Size | 0.1 mg |
| Concentration | n/a |
| Applications | Flow Cytometry (FC/FACS), C-ELISA |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Specificity: anti-human/pig VEGFR2 (epitope on the second extracellular immunoglobulinlike domain). The vascular endothelial growth factor receptor-2 (VEGFR-2) plays an important role in the control of angiogenesis. This molecule is expressed on the surface of circulating endothelial stem cells as well as on adult vascular endothelial cells and other cell types (1). It is a 200-kDa type I transmembrane protein, consisting of a 19 amino acid leader peptide, a 744 amino acid extracellular domain made up of 7 immunoglobulin-like domains, a 24 amino acid transmembrane region and a 568 amino acid cytoplasmic domain. Interactions with VEGF ligands will stimulate angiogenesis, required in wound healing but also misused by tumours to promote their |
| Immunogen | Immunogen: Genetic immunisation with cDNA encoding human VEGFR2 |
| Other Names | [vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor 2; vascular endothelial growth factor receptor 2; kinase insert domain receptor; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor flk-1; CD_antigen: CD309], [KDR; KDR; FLK1; CD309; VEGFR; VEGFR2; FLK1; VEGFR2; VEGFR-2; FLK-1; KDR] |
| Gene, Accession # | [VEGFR2], Gene ID: 3791, NCBI: NP_002244.1 |
| Catalog # | MBS468052 |
| Price | $505 |
| Order / More Info | Human VEGFR2 Antibody from MYBIOSOURCE INC. |
| Product Specific References | 1. Paz K, Zhu Z. (2005) Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. Front. Biosci. 10:1415-1439.2. Youssoufian H., Hicklin D.J., Rowinsky E.K. (2007) Monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin. Cancer Res. 13 (18 Suppl): 5544- 5528. |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies